Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
Tempest Therapeutics, Inc. (OVAS)
|
|
Income Statement |
|
|
|
Standardized | As Reported |
Annual | Quarterly | TTM |
|
In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Revenue growth | | | | | | | -100.0% | -100.0% |
Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross margin | | | | | | | | |
Selling, general and administrative [+] | 3.1 | 2.9 | 3.1 | 2.8 | 3.1 | 3.1 | 2.6 | 3.1 |
General and administrative | 3.1 | 2.9 | 3.1 | 2.8 | 3.1 | 3.1 | 2.6 | 3.1 |
Research and development | 4.4 | 4.7 | 5.8 | 6.0 | 5.7 | 5.1 | 4.7 | 4.6 |
Equity in earnings | | | | | | | | |
EBITDA [+] | -7.4 | -7.5 | -8.7 | -8.6 | -8.7 | -8.1 | -7.2 | -7.6 |
EBITDA growth | -14.7% | -7.4% | 20.5% | 12.3% | 29.3% | 59.5% | -200.3% | -238.3% |
EBITDA margin | | | | | | | | |
Depreciation and amortization | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
EBIT [+] | -7.5 | -7.6 | -8.9 | -8.8 | -8.8 | -8.2 | -7.3 | -7.7 |
EBIT growth | -14.9% | -7.1% | 21.7% | 13.4% | 29.3% | 59.2% | -202.2% | -242.4% |
EBIT margin | | | | | | | | |
Interest expense | 0.4 | 0.3 | 0.4 | 0.4 | 0.5 | 0.3 | 0.3 | 0.4 |
Interest expense | 0.4 | 0.3 | 0.4 | 0.4 | 0.5 | 0.3 | 0.3 | 0.4 |
Other income (expense), net [+] | 0.2 | 0.3 | 0.3 | 0.2 | 0.1 | 0.0 | -0.1 | 0.1 |
Other | 0.2 | -0.3 | | | 0.1 | 0.0 | 0.0 | |
Pre-tax income | -7.6 | -7.6 | -9.1 | -8.9 | -9.2 | -8.5 | -7.8 | -8.1 |
Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | -7.6 | -7.6 | -9.1 | -8.9 | -9.2 | -8.5 | -7.8 | -8.1 |
Net margin | | | | | | | | |
|
Basic EPS [+] | ($0.54) | ($0.55) | ($0.79) | ($0.66) | ($0.79) | ($1.18) | ($2.05) | ($1.21) |
Growth | -32.1% | -53.2% | -61.6% | -45.7% | -89.6% | -88.8% | 425.8% | -89.2% |
Diluted EPS [+] | ($0.54) | ($0.55) | ($0.79) | ($0.66) | ($0.79) | ($1.18) | ($2.05) | ($1.21) |
Growth | -32.1% | -53.2% | -61.6% | -45.7% | -89.6% | -88.8% | 425.8% | -89.2% |
|
Shares outstanding (basic) [+] | 14.1 | 13.8 | 11.5 | 13.6 | 11.6 | 7.2 | 3.8 | 6.7 |
Growth | 21.8% | 92.0% | 204.7% | 103.0% | 1150.6% | 1312.4% | -79.9% | 1287.7% |
Shares outstanding (diluted) [+] | 14.1 | 13.8 | 11.5 | 13.6 | 11.6 | 7.2 | 3.8 | 6.7 |
Growth | 21.8% | 92.0% | 204.7% | 103.0% | 1150.6% | 1312.4% | -79.9% | 1287.7% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|